This paper evaluates Fresenius, a German healthcare company and global leader in dialysis equipment and clinic services. It examines the company's business divisions, revenue breakdown by geography, and competitive position in the U.S. dialysis market, where Fresenius ranks second behind DaVita. The paper discusses the inelastic demand characteristics of the dialysis industry, the role of Medicare as a primary payer, and the sources — including annual reports, IBIS World data, academic papers, and business media — best suited for conducting a thorough industry and company analysis. Key financial figures and market dynamics are identified to frame the broader competitive landscape.
Fresenius is a healthcare company specializing in dialysis equipment and clinics, headquartered in Bad Homburg, Germany, just outside of Frankfurt. It is one of the global leaders in this field and operates an extensive network of dialysis clinics in the United States. The dialysis business is driven by the age and overall health of individuals in a given society, and there are a variety of payers depending on the country. Most dialysis patients require multiple clinic visits per week.
The core division, Fresenius Medical Care, accounts for $15.8 billion in revenue and over $1 billion in profits. The company also operates several smaller business units: Fresenius Kabi, which covers IV drugs, clinical nutrition, and medical devices; Fresenius Helios, which operates hospitals; and Fresenius Vamed, which manages projects and services for hospitals.
The market location under analysis is the United States. Fresenius is a global company whose revenues are fairly evenly split between Europe (44%) and North America (40%), but within that split the United States is the single largest market. The U.S. dialysis industry is valued at approximately $21 billion. Fresenius is the second-largest player in the American market, behind DaVita.
Demand in the industry is inelastic — people who need dialysis need it to survive, and in many cases they are not the direct payer. As a result, payers have relatively little bargaining power given the acute medical necessity that dialysis patients face.
Because Fresenius uses North America as its reporting unit, separating U.S. and Canadian revenues precisely can be difficult. However, based on population, it is reasonable to estimate that approximately 90% of total North American revenues originate in the United States when such estimates are required.
Conventional business media frequently covers large publicly-traded companies like Fresenius, which operates in a well-covered industry. According to industry sources, Fresenius holds over 50% market share in dialysis equipment manufacturing, competing in that segment with Swedish company Gambro. In the dialysis clinic segment, its primary competitor is DaVita, which holds the leading position in the U.S. market. The combination of manufacturing dominance and a significant clinic presence makes Fresenius a uniquely integrated competitor in the broader renal care ecosystem.
A number of sources can be used to gather information for analyzing this industry. Overall industry data is drawn from several different sources. The IBIS World report (2014) provides basic market data — the full report is costly to acquire, but would be an excellent source if obtainable. This report focuses specifically on dialysis centers, while Fresenius also manufactures equipment and sells to third-party dialysis centers, hospitals, and clinics. Although this distinction makes drilling down to precise data more challenging, valuable information remains available.
"DaVita rivalry, equipment market, and Gambro competition"
"Annual reports, IBIS World, academic papers, and media"
"Cited sources supporting the market analysis"
You’re 63% through this paper. Sign up to read the remaining 3 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.